ReviewInfectious agents and cancer2025
An overview of hepatitis B virus in gastric carcinogenesis: from clinical association to molecular mechanisms.
Review in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Previous studies have established that Hepatitis B virus (HBV) infection contributes to the development of cirrhosis and hepatocellular carcinoma (HCC). In recent years, growing attention has been directed towards the association between HBV and extrahepatic malignant tumors, particularly gastric cancer (GC), with increasing evidence suggesting that HBV infection may elevate the risk of GC. Several meta-analyses have examined the link between HBV and GC. However, the underlying pathogenic mechanisms remain poorly understood. This study conducts a systematic review of existing research to investigate the association between HBV infection and GC risk. Additionally, it offers a comprehensive analysis of the epidemiological data, virological characteristics, and molecular mechanisms. The available evidence suggests that HBV may contribute to GC development and progression through mechanisms such as HBV DNA integration, regulation of HBx protein, chronic inflammation, and immune dysregulation. However, limitations in the current literature—such as reliance on single-source samples, insufficient control of confounding factors, and limited mechanistic studies—should be acknowledged. Large-scale, multicenter, prospective studies with clearly defined mechanisms are needed to further clarify the causal relationship between HBV and GC and to identify potential biomarkers. In conclusion, addressing HBV-related GC is a critical clinical and public health priority.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.